

1 **Mitochondrial-Derived Compartments Facilitate Cellular Adaptation to Amino**  
2 **Acid Stress**

3

4 **Max-Hinderk Schuler<sup>1#</sup>, Alyssa M. English<sup>1#</sup>, Tianyao Xiao<sup>1</sup>, Thane J. Campbell<sup>1</sup>,**  
5 **Janet M. Shaw<sup>1</sup>, and Adam L. Hughes<sup>1,2,\*</sup>**

6

7 <sup>1</sup>Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT,  
8 84112, USA

9

10 <sup>2</sup>Lead Contact

11

12 #These authors contributed equally to this work

13 \*Correspondence: [hughes@biochem.utah.edu](mailto:hughes@biochem.utah.edu)

14

15

16

17

18

19

20

21

22

23

24

25 **PAPER SUMMARY**

26 Amino acids are essential building blocks of life. However, increasing evidence  
27 suggests that elevated amino acids cause cellular toxicity associated with numerous  
28 metabolic disorders. How cells cope with elevated amino acids remains poorly  
29 understood. Here, we show that a previously identified cellular structure, the  
30 mitochondrial-derived compartment (MDC), functions to protect cells from amino acid  
31 stress. In response to amino acid elevation, MDCs are generated from mitochondria,  
32 where they selectively sequester and deplete SLC25A nutrient carriers and their  
33 associated import receptor Tom70 from the organelle. Generation of MDCs promotes  
34 amino acid catabolism, and their formation occurs simultaneously with transporter  
35 removal at the plasma membrane via the multi-vesicular body (MVB) pathway.  
36 Combined loss of vacuolar amino acid storage, MVBs and MDCs renders cells sensitive  
37 to high amino acid stress. Thus, we propose that MDCs operate as part of a  
38 coordinated cell network that facilitates amino acid homeostasis through post-  
39 translational nutrient transporter remodeling.

40

41

42

43

44

45

46

47

48 **STAR METHODS**

49

50 **Resource Availability**

51 Lead Contact

52 Further information and requests for resources and reagents should be directed to and  
53 will be fulfilled by the Lead Contact, Adam Hughes ([hughes@biochem.utah.edu](mailto:hughes@biochem.utah.edu)). All  
54 unique/stable reagents generated in this study are available from the Lead Contact  
55 without restrictions.

56

57 Materials Availability

58 All unique/stable reagents generated in this study are available from the Lead Contact  
59 without restrictions.

60

61 Data and Code Availability

- 62
- 63 • Metabolomics data have been deposited at and are publicly available as of the  
64 date of the publication. Accession numbers are listed in the Key Resources  
65 Table. All other data reported in this paper will be shared by the lead contact  
66 upon request.
  - 67 • This paper does not report original code.
  - 68 • Any additional information required to reanalyze the data reported in this paper is  
69 available from the lead contact upon request.

69

70 **Experimental Model and Subject Details**

71 Yeast Strains

72 All yeast strains are derivatives of *Saccharomyces cerevisiae* S288c (BY)  
73 (Brachmann et al., 1998). Strains expressing fluorescently tagged *TOM70*, *TIM50*,  
74 *TOM20*, *ILV2*, *TCD2*, *BAP2*, *OAC1*, *ODC1*, *MTM1*, *YMC2* and/or AID\*-6xFLAG/6xFLAG  
75 tagged *VMA2* from their native loci were created by one step PCR-mediated carboxy-  
76 terminal endogenous epitope tagging using standard techniques and oligo pairs listed in  
77 Table S2. Plasmid templates for fluorescent epitope tagging were from the pKT series  
78 of vectors (Sheff and Thorn, 2004). Plasmids used for AID\*-6xFLAG/6xFLAG tagging  
79 and integration of GPD-OsTir1 into the *LEU2* locus are described below. Correct  
80 integrations were confirmed by a combination of colony PCR across the chromosomal  
81 insertion site and correctly localized expression of the fluorophore by microscopy.  
82 Deletion strains for *TOM70*, *TOM71*, *TOM20*, *GEM1*, *PEP4*, *ILV2*, *BAT1* and/or *BAT2*,  
83 *VPS27* and/or *DID4* were generated by one step PCR-mediated gene replacement with  
84 the indicated selection cassette using standard techniques and oligo pairs listed in  
85 Table S2. Plasmid templates for gene replacement were from the pRS series of vectors  
86 (Sikorski and Hieter, 1989). Correct insertion of the selection cassette into the target  
87 gene was confirmed by colony PCR across the chromosomal insertion site. Yeast  
88 strains constitutively expressing *TOM70*, *TOM20*, *TIM50* or the indicated mitochondrial  
89 carrier protein from the GPD promoter were generated by integration of the expression  
90 cassette into yeast chromosome I (199456-199457). Plasmids for integration of the  
91 GPD-driven expression cassette are described below. Correct insertion of the  
92 expression cassette into chromosome I was confirmed by colony PCR across the  
93 chromosomal insertion site.

94 *Wild-type* yeast strain AHY4706, which was rendered prototrophic with pHLUM  
95 (see below) to prevent complications caused by amino acid auxotrophies in the BY  
96 strain background, was used to quantify amino acid dependencies of MDC formation  
97 and for analysis of whole cell metabolite levels. *Wild-type* yeast strains AHY5082,  
98 AHY7053, AHY7620, AHY8529, AHY8531, AHY6257, AHY10448, AHY10466,  
99 AHY10468 and AHY10470 were used for super resolution and/or time-lapse imaging.  
100 AHY1447 and AHY10546 were used for indirect immuno fluorescence analysis. *Wild-*  
101 *type* and *gem1* $\Delta$  yeast strains AHY4706, AHY4057, AHY6259, AHY7802, AHY10448,  
102 AHY10554, AHY10466, AHY10552, AHY10468, AHY10548, AHY10470, AHY10550,  
103 AHY7808, AHY7816, AHY7804 and AHY7806 were used for quantification of MDC-  
104 dependent removal of proteins from mitochondria and protein enrichment in the MDC.  
105 Metabolite analysis was performed in AHY4706, AHY9666, BY4741, AHY4230,  
106 AHY9873 and AHY10141. Growth assays were performed with BY4741, AHY4230,  
107 AHY9873, AHY10141, AHY9913 and AHY10145. A complete list of all strains used in  
108 this manuscript can be found in the Key Resources Table.

109

### 110 Yeast Cell Culture and Media

111 Yeast cells were grown exponentially for 15 hours at 30 °C to a maximum density  
112 of  $6 \times 10^6$  cells/mL before the start of all experiments described in the paper, including  
113 MDC and spot assays. This period of overnight log-phase growth was carried out to  
114 ensure vacuolar and mitochondrial uniformity across the cell population and is essential  
115 for consistent MDC activation. Cells were cultured as indicated in media containing high  
116 amino acids (1 % yeast extract, 2 % peptone, 0.005 % adenine, 2 % glucose) or low

117 amino acids (0.67 % yeast nitrogen base without amino acids, 2 % glucose,  
118 supplemented nutrients 0.074 g/L each adenine, alanine, arginine, asparagine, aspartic  
119 acid, cysteine, glutamic acid, glutamine, glycine, histidine, myo-inositol, isoleucine,  
120 lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, uracil,  
121 valine, 0.369 g/L leucine, 0.007 g/L para-aminobenzoic acid). For growth in medium  
122 lacking all amino acids (0.67 % yeast nitrogen base without amino acids, 2 % glucose),  
123 cells were cultured in low amino acid medium and then shifted to medium containing no  
124 amino acids at time of drug treatment. Where casamino acids were added to low or no  
125 amino acid media, casamino acids were added at time of drug treatment to a final  
126 concentration of 2 %. For single amino acid re-addition experiments, individual amino  
127 acids were added to medium containing low amino acids at the time of drug treatment.  
128 All amino acids were added to a final concentration of 20 mg/mL, except indicated  
129 otherwise, with the exception of cysteine and tyrosine, which were added at final  
130 concentrations of 5 mg/mL and 1 mg/mL respectively, due to toxicity and/or solubility  
131 issues. Leucine and methionine catabolites were added at a final concentration of  
132 10 mM at the time of drug treatment. Drugs were added to cultures at final  
133 concentrations of concanamycin A (500 nM), cycloheximide (10 µg/mL), rapamycin  
134 (250 nM), torin1 (5 µM), antimycin A (40 µM), FCCP (10 µM), oligomycin (10 µM), H<sub>2</sub>O<sub>2</sub>  
135 (10 µM), CoCl<sub>2</sub> (1 mM), tunicamycin (5 µg/ml) and BPS (250 µM). Iron was added to  
136 cultures as (NH<sub>4</sub>)<sub>2</sub>Fe(SO<sub>4</sub>)<sub>2</sub>(H<sub>2</sub>O)<sub>6</sub> at a final concentration of 2 mM.

137

## 138 **Method Details**

139

140 Extraction of Whole Cell Metabolites from Yeast

141 For analysis of whole cell metabolite levels in high amino acid media, cells were  
142 grown exponentially in high amino acid media for 15 hours to a maximum density of  
143  $6 \times 10^6$  cells/mL, resuspended in fresh media to a maximum density of  $1.85 \times 10^7$   
144 cells/mL, and treated for three hours with the indicated drugs.  $5 \times 10^7$  total yeast cells  
145 were harvested by centrifugation for two minutes at  $5000 \times g$ , washed once with ice cold  
146 water, and cell pellets were shock frozen in liquid nitrogen. Glucose tracing experiments  
147 were performed as described above, but cells were resuspended in high amino acid  
148 media containing 2 %  $^{13}C_6$ -Glucose (Cambridge Isotope Laboratories). For analysis of  
149 whole cell metabolite levels in low amino acid media supplemented with leucine, cells  
150 were grown exponentially in low amino acid media for 15 hours to a maximum density of  
151  $6 \times 10^6$  cells/mL, resuspended in low amino acid media supplemented with 10 mg/ml  
152 leucine to a maximum density of  $1.85 \times 10^7$  cells/mL and treated for three hours with  
153 ConcA.  $5 \times 10^7$  total yeast cells were harvested by fast quenching into four volumes of  
154 100 % methanol at  $-40^\circ C$  (final 80 % methanol), pelleted by centrifugation for two  
155 minutes at  $5000 \times g$  in a pre-cooled rotor at  $-20^\circ C$ , washed once with  $-40^\circ C$  cold 80 %  
156 methanol, and cell pellets were shock frozen in liquid nitrogen.

157 Whole cell metabolites were extracted from yeast cell pellets as previously  
158 described with slight modifications (Canelas et al., 2009). Briefly, 0.4  $\mu g$  of the internal  
159 standard succinic- $d_4$  acid (Sigma Aldrich 10907HD) was added to each sample.  
160 Subsequently, 5 mL of boiling 75% EtOH were added to each cell pellet, followed by  
161 vortex mixing and incubation at  $90^\circ C$  for five minutes. Cell debris were removed by  
162 centrifugation for three minutes at  $7000 \times g$  and supernatants were transferred to new

163 tubes and dried *en vacuo*. Pooled quality control samples were made by removing a  
164 fraction of collected supernatant from each sample and process blanks were made  
165 using only extraction solvent and no cell culture pellet.

166

#### 167 GC-MS Analysis

168 GC-MS analysis was performed with an Agilent 5977B GC-MS MSD-HES or an Agilent  
169 7200 GC-QToF-MS both using an Agilent 7693A automatic liquid sampler. Dried  
170 samples were suspended in 40  $\mu$ l of a 40 mg/ml O-methoxylamine hydrochloride (MOX)  
171 (MP Bio #155405) in dry pyridine (EMD Millipore #PX2012-7) and incubated for one  
172 hour at 37 °C in a sand bath. 25  $\mu$ l of this solution was added to auto sampler vials. 60  
173  $\mu$ l of N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA with 1% TMCS, Thermo  
174 #TS48913) was added automatically via the auto sampler and incubated for 30 minutes  
175 at 37 °C. After incubation, samples were vortexed and 1  $\mu$ l of the prepared sample was  
176 injected into the gas chromatograph inlet in the split mode with the inlet temperature  
177 held at 250°C. A 10:1 split ratio was used for analysis of the majority of metabolites. For  
178 those metabolites that saturated the instrument at the 10:1 split concentration, a split of  
179 100:1 was used for analysis. The gas chromatograph had an initial temperature of 60°C  
180 for one minute followed by a 10°C/min ramp to 325°C and a hold time of 5 minutes  
181 followed by a 100°C/min ramp to 375°C. A 30-meter Phenomenex Zebron AB-5HT with  
182 5m inert Guardian capillary column was employed for chromatographic separation.  
183 Helium was used as the carrier gas at a rate of 1 ml/min.

184 Data was collected using MassHunter software (Agilent). Metabolites were  
185 identified and their peak area was recorded using MassHunter Quant. This data was

186 transferred to an Excel spread sheet (Microsoft, Redmond WA). Metabolite identity was  
187 established using a combination of an in-house metabolite library developed using pure  
188 purchased standards, the NIST library, and the Fiehn library. Values for each metabolite  
189 were normalized to the internal standard in each sample and are displayed as fold  
190 change compared to the control sample except otherwise indicated in the figure legend.  
191 For isotope tracer analysis the area under the curve for each isotope was extracted  
192 using MHQuant software (Agilent). This data was exported as a.csv file and isotopically  
193 corrected using an in house modified version of DeuteRater (Naylor et al., 2017). All  
194 error bars show the mean  $\pm$  SE from  $N =$  three to four biological replicates analyzed in  
195 the same GC-MS run.

196

## 197 REFERENCES

- 198 Brachmann, C.B., Davies, A., Cost, G.J., Caputo, E., Li, J., Hieter, P., and Boeke, J.D. (1998).  
199 Designer deletion strains derived from *Saccharomyces cerevisiae* S288C: a useful set of strains  
200 and plasmids for PCR-mediated gene disruption and other applications. *Yeast* *14*, 115-132.  
201 10.1002/(SICI)1097-0061(19980130)14:2<115::AID-YEA204>3.0.CO;2-2.
- 202 Canelas, A.B., ten Pierick, A., Ras, C., Seifar, R.M., van Dam, J.C., van Gulik, W.M., and  
203 Heijnen, J.J. (2009). Quantitative evaluation of intracellular metabolite extraction techniques for  
204 yeast metabolomics. *Anal Chem* *81*, 7379-7389. 10.1021/ac900999t.
- 205 Naylor, B.C., Porter, M.T., Wilson, E., Herring, A., Lofthouse, S., Hannemann, A., Piccolo,  
206 S.R., Rockwood, A.L., and Price, J.C. (2017). DeuteRater: a tool for quantifying peptide isotope  
207 precision and kinetic proteomics. *Bioinformatics* *33*, 1514-1520. 10.1093/bioinformatics/btx009.
- 208 Sheff, M.A., and Thorn, K.S. (2004). Optimized cassettes for fluorescent protein tagging in  
209 *Saccharomyces cerevisiae*. *Yeast* *21*, 661-670. 10.1002/yea.1130.
- 210 Sikorski, R.S., and Hieter, P. (1989). A system of shuttle vectors and yeast host strains designed  
211 for efficient manipulation of DNA in *Saccharomyces cerevisiae*. *Genetics* *122*, 19-27.  
212